Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.19 USD
Change Today +0.002 / 1.09%
Volume 695.6K
HEB On Other Exchanges
As of 8:04 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Key Developments

U.S. District Court Judge Approves Hemispherx Biopharma's $2.7 Million Settlement

U.S. District Court judge approved a $2.75 million settlement that will resolve a class-action lawsuit brought by the shareholders of Hemispherx BioPharma, which alleged the company made 'material misrepresentations and omissions' regarding the status of a new drug application for its lead new drug candidate. The lawsuit - filed on behalf of investors who purchased or acquired Hemispherx stock between March 14, 2012 through December 20, 2012 - alleged Hemispherx representatives 'touted purportedly positive results from Ampligen's clinical trials'. The settlement includes a deadline of August 21, 2015 for shareholders to file claims.

Hemispherx Biopharma, Inc. Submits Application for Orphan Drug Designation to European Medicines Agency for Alferon N Injection®

Hemispherx Biopharma, Inc. announced that they have submitted an application for orphan drug designation to the European Medicines Agency (EMA) for Alferon N Injection®, an experimental therapeutic, to treat Middle East Respiratory Syndrome (MERS). The EMA has determined the application to be valid, and the Committee for Orphan Medicinal Products (COMP) has initiated the official review process. It is anticipated that the COMP will give an opinion on the application within the next 90 days. There are significant benefits for achieving Orphan Designation, including eligibility for grants from EU and Member State programs. Designated orphan medicines are assessed for marketing authorization centrally in the European Union with reductions/waivers in the fees and costs of the overall regulatory process. The designation allows companies to make a single application to the European Medicines Agency, resulting in a single opinion and a single decision from the European Commission, valid in all EU Member States. Authorized orphan medications, once commercially approved, receive benefits including ten years of complete protection from market competition with similar medicines.

Hemispherx Biopharma, Inc. Amends Restated and Amended By-Laws

On June 23, 2015, the Board of Hemispherx Biopharma, Inc. amended restated and amended By-Laws in accordance with a directive of Board of Directors to reduce the quorum, solely for the 2015 annual meeting of stockholders, from holders of a majority in voting power of the outstanding shares of stock to the holders of 40% in voting power of the outstanding shares of stock. The Board reduced the quorum, after consultation with the company's proxy advisory firm and due to low voter turnout experienced in the past.

Hemispherx Biopharma, Inc. Announces Preliminary Approval of Securities Class Action Settlement

Hemispherx Biopharma announced that the United States District Court for the Eastern District of Pennsylvania has granted preliminary approval of a settlement of the currently pending securities class action, Frater versus Hemispherx Biopharma, Inc. A final settlement hearing has been scheduled for July 22, 2015. The settlement will be paid from the company's insurance coverage and will not result in the payment of any funds by the company. The settlement expressly is not an admission of culpability by Hemispherx or any of the individual defendants.

Hemispherx Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

Hemispherx Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were $36,000, compared to $76,000 for the same quarter ended March 31, 2014. Operating loss was $4.92 million, compared to an operating loss of $5.11 million for the same quarter ended March 31, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.19 USD +0.002

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $328.87 USD -9.12
AstraZeneca PLC 4,322 GBp +2.00
Baxter International Inc $40.01 USD +1.51
Medigene AG €9.66 EUR -0.04
Sarepta Therapeutics Inc $31.76 USD +0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 249.0x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 162.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at